# Trulieve Cannabis Corp. Subordinate Voting Shares (TRLV) fundamentals

Data as of 2026-09-08. NYSE, United States. Sector: Healthcare / Biotechnology. Price $12.11, market value $2.3 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Trulieve Cannabis Corp. Subordinate Voting Shares reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **PEG: 0.82**. A PEG of 0.82 means the P/E is low relative to expected earnings growth: the market is not paying much for that growth.
- **Price / sales: 2.0×**. Each dollar of revenue is priced at 2.0×.
- **Price / book: 2.0×**. The shares trade at 2.0× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: 8.3%** (5-yr avg 5.7%). Free cash flow equals 8.3% of the market value, above its five-year average of 5.7%, so the shares are cheaper on cash than they have usually been. Above 5% is generally attractive.

## Profitability
- **Gross margin: 59.5%**. Trulieve Cannabis Corp. Subordinate Voting Shares keeps 59.5% of revenue after the direct cost of what it sells.
- **Operating margin: -24.3%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: -10.3%**. The company reported a net loss over the last twelve months.
- **Return on equity: -10.7%**. Return on equity is negative because earnings are negative.
- **Return on invested capital: -21.4%**. Return on all capital, debt included, is -21.4%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: -17.7%**. Each dollar of assets produces -17.7% of profit.

## Growth
- **Revenue growth (1 yr): -0.4%** (3-yr -1.0%/yr, 5-yr 17.8%/yr). Revenue fell 0.4% over the last year, against 17.8% a year compounded over five years: growth is slowing.
- **EPS growth (1 yr): 26.6%**. Earnings per share rose 26.6%, faster than revenue, so margins expanded or the share count shrank.

## Financial health
- **Debt to equity: 0.12**. Debt is 0.12 times equity: a conservative balance sheet.
- **Net debt / EBITDA: 0.7×**. It would take 0.7 years of operating earnings to repay net borrowings, within the comfortable range.
- **Altman Z-score: 2.11**. A Z-score of 2.11 is in the grey zone; not distressed, not clearly safe.
- **Piotroski F-score: 5/9**. 5 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. Trulieve Cannabis Corp. Subordinate Voting Shares does not currently pay a dividend.

## Price and momentum
- **Total return (1 yr): 67.0%** (YTD 39.4%, 3-mo 3.2%). The shares are up 67.0% over twelve months including dividends.
- **From 52-week high: -8.8%** (162.3% above the low). Trading 9% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 72**. An RSI of 72 is in overbought territory; short-term pullbacks are common from here.
- **Beta (1 yr): 0.95** (volatility 114%). Beta of 0.95 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=TRLV · Page: https://foliofundamentals.com/stocks/trlv

Not investment advice.